By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...

A whole-food plant-based diet can significantly increase weight loss for men with prostate cancer and overweight or obesity ...

Only men with a dangerous genetic variant and a family history of cancer should be offered screening, say UK advisors.

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

The majority of men in the UK will not be offered prostate cancer screening following a final recommendation from a committee ...

The UK's National Screening Committee has recommended that only a very small group of men at high risk of prostate cancer ...